ReviewFrontiers in medicine2026
Traditional Chinese medicine regulating Wnt/β-catenin and OPG/RANKL/RANK pathways in osteoporosis: a narrative review based on bone coupling and pathological subtype differences.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoporosis (OP) is characterized by bone coupling imbalance-insufficient osteoblast-mediated formation and excessive osteoclast-mediated resorption. Among multiple signaling networks involved in bone remodeling, the canonical Wnt/beta-catenin pathway and the osteoprotegerin/receptor activator of nuclear factor-kappaB ligand/receptor activator of nuclear factor-kappaB axis, namely the OPG/RANKL/RANK axis, were selected because they represent two central and mutually interacting regulatory systems governing osteoblast differentiation and osteoclastogenesis. Traditional Chinese Medicine (TCM) offers multi-target potential for regulating bone homeostasis. Objective: This narrative review examines TCM interventions targeting Wnt/β-catenin and OPG/RANKL/RANK pathways in OP, emphasizing bone coupling and pathological subtype differences. Methods: Structured literature searches (PubMed, Web of Science Core Collection, CNKI, Wanfang, cqVIP; 2000-2025) with OCEBM/SYRCLE evidence grading were conducted. Conclusion: TCM suggests bidirectional bone coupling regulation through multi-target mechanisms, but evidence remains predominantly preclinical (Levels 4-5). Pharmacokinetic barriers (low oral bioavailability of icariin, berberine), safety concerns (Xianling Gubao hepatotoxicity), and lack of fracture-endpoint RCTs limit clinical translation. Future research should prioritize target-engagement biomarkers, bone-targeted delivery, and adequately powered RCTs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.